The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase II trial of pembrolizumab in patients with brain metastases.
 
Priscilla Kaliopi Brastianos
Honoraria - Pfizer
Consulting or Advisory Role - Advise Connect Inspire; Axiom Health; Dantari Pharmaceuticals; ElevateBio; Kazia Therapeutics; Medscape; MPM Capital; Sintetica; Voyager Therapeutics
Research Funding - Kinnate Biopharma (Inst); Lilly (Inst); Merck (Inst); Mirati Therapeutics (Inst)
 
Albert Eusik Kim
No Relationships to Disclose
 
Anita Giobbie-Hurder
No Relationships to Disclose
 
Eudocia Quant Lee
Honoraria - Medlink
Consulting or Advisory Role - Medscape
Patents, Royalties, Other Intellectual Property - Royalties from Wolter Kluwer for Up to Date, Inc
 
Nancy U. Lin
Stock and Other Ownership Interests - Artera
Consulting or Advisory Role - Affinia Therapeutics; Aleta Biotherapeutics; Artera; AstraZeneca; Blueprint Medicines; Daiichi Sankyo; Denali Therapeutics; Johnson & Johnson/Janssen; Olema Pharmaceuticals; Pfizer; Prelude Therapeutics; Puma Biotechnology; Seagen; Voyager Therapeutics
Research Funding - Genentech (Inst); Merck (Inst); Olema Pharmaceuticals (Inst); Pfizer (Inst); Seagen (Inst); Zion Pharma (Inst)
Patents, Royalties, Other Intellectual Property - Royalties for chapter in Up-to-Date regarding management of breast cancer brain metastases; Royalties, Jones & Bartlett
 
Beth Overmoyer
No Relationships to Disclose
 
Patrick Y. Wen
Consulting or Advisory Role - AstraZeneca; Bayer; Black Diamond Therapeutics; Boehringer Ingelheim; Boston Pharmaceuticals; Celularity; Chimerix; Day One Biopharmaceuticals; ElevateBio; Genenta Science; GlaxoSmithKline; Insightec; Integral Health; Karyopharm Therapeutics; Merck; Mundipharma; Novartis; Novocure; Novocure; Nuvation Bio; Prelude Therapeutics; Prelude Therapeutics; Sagimet Biosciences; Sapience Therapeutics; Servier; Servier; Vascular Biogenics; VBI Vaccines
Research Funding - AstraZeneca (Inst); Bayer (Inst); Beigene (Inst); Celgene (Inst); Chimerix (Inst); Karyopharm Therapeutics (Inst); Kazia Therapeutics (Inst); Lilly (Inst); MediciNova (Inst); Merck (Inst); Novartis (Inst); Nuvation Bio (Inst); Oncoceutics (Inst); Puma Biotechnology (Inst); Servier (Inst); Vascular Biogenics (Inst); VBI Vaccines (Inst)
 
Lakshmi Nayak
Honoraria - Ono Pharmaceutical
Consulting or Advisory Role - BraveBio; Genmab; Ono Pharmaceutical
Research Funding - AstraZeneca (Inst); Kazia Therapeutics (Inst); Merck (Inst)
Travel, Accommodations, Expenses - Ono Pharmaceutical
 
Justine Vanessa Cohen
Consulting or Advisory Role - Regeneron; Sanofi/Regeneron
 
Jorg Dietrich
Patents, Royalties, Other Intellectual Property - UpToDate Author
Expert Testimony - White and Williams LLP
 
Rebecca Suk Heist
Consulting or Advisory Role - Abbvie; Claim Therapeutics; Daichii Sankyo; Daichii Sankyo; EMD Serono/Merck; EMD Serono/Merck; Lilly; Novartis; Regeneron; Sanofi
Research Funding - Abbvie (Inst); Agios (Inst); Corvus Pharmaceuticals (Inst); Daiichi Sankyo (Inst); Daiichi Sankyo (Inst); Erasca, Inc (Inst); Exelixis (Inst); Exelixis (Inst); Lilly (Inst); Mirati Therapeutics (Inst); Mythic Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); Pfizer (Inst); Roche (Inst); Turning Point Therapeutics (Inst)
 
Ian E. Krop
Employment - Freeline Therapeutics (I); PureTech (I)
Leadership - Freeline Therapeutics (I); PureTech (I)
Stock and Other Ownership Interests - Freeline Therapeutics (I); PureTech (I)
Honoraria - AstraZeneca; Genentech/Roche
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo; Genentech/Roche; Macrogenics; Merck; Novartis; Seagen
Research Funding - Genentech (Inst); Macrogenics (Inst); Pfizer (Inst)
 
Donald P. Lawrence
No Relationships to Disclose
 
Erica L. Mayer
Consulting or Advisory Role - AstraZeneca; Diaccurate; Gilead Sciences; Lilly; Novartis
 
Eric P. Winer
Consulting or Advisory Role - Carrick Therapeutics; Jounce Therapeutics; Leap Therapeutics
Research Funding - Genentech (Inst)
 
Helen Alice Shih
Honoraria - UpToDate
Consulting or Advisory Role - Advanced Accelerator Applications/Novartis; SERVIER
Research Funding - Abbvie (Inst)
Other Relationship - UpToDate
 
Kevin S. Oh
No Relationships to Disclose
 
Daniel P. Cahill
Stock and Other Ownership Interests - Pyramid Biosciences
Consulting or Advisory Role - GlaxoSmithKline; Lilly
 
Elizabeth R Gerstner
Consulting or Advisory Role - Array BioPharma (I); MyoKardia (I)
Other Relationship - Midatech Pharma
 
Ryan J. Sullivan
Consulting or Advisory Role - alkermes; Asana Biosciences; AstraZeneca; Bristol-Myers Squibb; Eisai; Iovance Biotherapeutics; Merck; Novartis; OncoSec; Pfizer; Replimune
Research Funding - Aeglea Biotherapeutics (Inst); Amgen (Inst); Asana Biosciences (Inst); BeiGene (Inst); BioMed Valley Discoveries (Inst); Compugen (Inst); Deciphera (Inst); Lilly (Inst); Marengo Therapeutics (Inst); Merck (Inst); Moderna Therapeutics (Inst); Neon Therapeutics (Inst); Pfizer (Inst); Roche/Genentech (Inst); Rubius Therapeutics (Inst); Sanofi (Inst); Strategia (Inst); Strategia (Inst); Synthekine (Inst); Viralytics (Inst)